Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Become a member for free
Sign up
New member
Sign up for FREE
New customer
Discover our services
English (USA)
English (UK)
English (Canada)
Deutsch (Deutschland)
Deutsch (Schweiz)
Español
Français (France)
Français (Suisse)
Italiano
Nederlands (Nederland)
Nederlands (België)
Markets
Equities
North America
Europe
Asia
Oceania
Middle East
»
More Equities
Indexes
S&P 500
DOW JONES
NASDAQ 100
EURO STOXX 50
NIKKEI 225
»
More Indexes
Currency / Forex
USD / EUR
USD / CAD
USD / MXN
USD / BRL
USD / INR
»
More Currencies
Commodities
GOLD
Crude Oil (WTI)
Crude Oil (BRENT)
SILVER
PLATINUM
»
More Commodities
Trackers & ETF
Rankings and News
Advanced Search
Cryptocurrencies
BITCOIN
ETHEREUM
News
Latest News
Companies
Markets
Economy
Currency / Forex
Commodities
Interest Rates
Business Leaders
Cryptocurrencies
Cybersecurity
Economic Calendar
Listed companies
Analyst Reco.
Rumors
IPOs
Capital Markets Transactions
New Contracts
Profit Warnings
Appointments
Press Releases
Events
Security Transactions
Financial Calendar
Sector News
Energy
Basic Materials
Industrials
Consumer Cyclical
Consumer Non-Cyclical
Financials
Healthcare
Technology
Telecommunications Services
Utilities
Analysis
All Analysis
Must Read
Daily Briefing
Weekly market update
Stock Trading Strategies
Stock Picks
All Stock Picks
Subscribe
Portfolios
My Portfolio
Virtual Portfolios
MarketScreener Portfolios
USA Portfolio
European Portfolio
Asian Portfolio
Watchlists
My Watchlists
Watchlists
My previous session
My most visited
Most popular
Investment Style
Trend-Following Stocks
Multibaggers
Momentum stocks
Undervalued stocks
Quality stocks
Growth stocks
Investment Themes
Gold and Silver
The Internet of Things
Pricing Power
Warren Buffett
Semiconductors
In Vino Veritas
Rankings
Top News
Most Read News
Hot News
Top Fundamentals
Top Capitalization
Top Yield
Top PER
Top Consensus
Top Fundamentals
Top ranking ESG
Top Technicals
Top RSI
Unusual volumes
Top Gaps
Top STIM
Breakouts
Trends
Top Movers
Top USA
Top Canada
Top U.K.
Top Germany
Top Europe
Top Asia
Screeners
Investment Themes
Gold and Silver
The Internet of Things
Pricing Power
Warren Buffett
Semiconductors
In Vino Veritas
Technical Rankings
Oversold stocks
Overbought stocks
Close to resistance
Close to support
Accumulation Phases
Most volatile stocks
Fundamental Rankings
Top Investor Rating
Top Trading Rating
Top Consensus
Growth stocks
Yield stocks
Low valuations
Stock Screener Home
My Screeners
All my stocks
Watchlists
Virtual Portfolios
Tools
MarketScreener tools
Stock Screener
iPhone App
Expert tools
Stock Screener PRO
Portfolio Creator
Event Screener
Dynamic Chart
Financial Calendar
Economic Calendar
Apprendre la bourse
ProRealTime Trading
Our Services
MarketScreener Portfolios
European Portfolio
USA Portfolio
Asian Portfolio
Our Stock Picks
Thematic Investment Lists
Stock Screener
Homepage
Equities
Canada
Toronto Stock Exchange
Medicenna Therapeutics Corp.
News
Summary
MDNA
CA58490H1073
MEDICENNA THERAPEUTICS CORP.
(MDNA)
Add to my list
Report
Delayed Toronto Stock Exchange -
05/16 03:58:59 pm EDT
1.360
CAD
-4.90%
05/11
Medicenna Presents Phase 1/2 ABILITY Data Highlighting MDNA11's "Favorable" Clinical Profile at Cancer Immunotherapy Meet
MT
05/11
Medicenna Therapeutics Corp. Presents Phase 1/2 Ability Study Data Highlighting Mdna11's Favorable Clinical Profile At the 2022 Frontiers in Cancer Immunotherapy Meeting
CI
05/11
Medicenna Presents Phase 1/2 ABILITY Study Data Highlighting MDNA11's Favorable Clinical Profile at the 2022 Frontiers in Cancer Immunotherapy Meeting
AQ
Summary
Quotes
Charts
News
Ratings
Calendar
Company
Financials
Consensus
Revisions
Summary
Most relevant
All News
Analyst Reco.
Other languages
Press Releases
Official Publications
Sector news
Medicenna Therapeutics up 12.7% in US Trade, Details Management Change, Appoints Development Advisory Committee
01/18/2022 | 07:07am EDT
Send by mail :
Name :
First name :
From
*
:
To
*
:
(You can enter multiple email addresses separated by commas)
Message :
*
Required fields
© MT Newswires 2022
Stocks mentioned in the article
Change
Last
1st jan.
AMGEN INC.
0.19%
243.87
8.40%
MEDICENNA THERAPEUTICS CORP.
-4.90%
1.36
-35.24%
NOVARTIS AG
0.16%
87.64
9.03%
ON SEMICONDUCTOR CORPORATION
-1.83%
55.15
-18.80%
All news about MEDICENNA THERAPEUTICS CORP.
05/11
Medicenna Presents Phase 1/2 ABILITY Data Highlighting MDNA11's "Favorable" Clinical Pr..
MT
05/11
Medicenna Therapeutics Corp. Presents Phase 1/2 Ability Study Data Highlighting Mdna11'..
CI
05/11
Medicenna Presents Phase 1/2 ABILITY Study Data Highlighting MDNA11's Favorable Clinica..
AQ
05/02
Medicenna up 7.3% in US Pre-Market as Details Promising New Clinical Data From Phase 1/..
MT
05/02
MEDICENNA THERAPEUTICS
: Announces New Clinical Data Showing Dose-Dependent Stimulation of..
PU
05/02
Medicenna Announces New Clinical Data Showing Dose-Dependent Stimulation of Anti-Cancer..
AQ
05/02
Medicenna Therapeutics Corp. Announces New Clinical Data Showing Dose-Dependent Stimula..
CI
04/27
MEDICENNA THERAPEUTICS
: to Present at the 2022 Bloom Burton & Co. Healthcare Investor Con..
PU
04/27
Medicenna Therapeutics to Present at the 2022 Bloom Burton & Co. Healthcare Investor Co..
AQ
04/08
Medicenna Presents Preclinical Data Showing Anti-Cancer Activity at the AACR Annual Mee..
MT
More news
Analyst Recommendations on MEDICENNA THERAPEUTICS CORP.
2021
MEDICENNA THERAPEUTICS
: HC Wainwright Adjusts Price Target on Medicenna Therapeutics to $..
MT
2020
MEDICENNA THERAPEUTICS
: Oppenheimer Starts Medicenna Therapeutics at Outperform With $12 ..
MT
More recommendations
Financials
CAD
USD
Sales 2022
-
-
-
Net income 2022
-25,1 M
-19,5 M
-19,5 M
Net Debt 2022
-
-
-
P/E ratio 2022
-2,92x
Yield 2022
-
Capitalization
75,6 M
58,5 M
58,5 M
Capi. / Sales 2022
-
Capi. / Sales 2023
52,6x
Nbr of Employees
13
Free-Float
66,9%
More Financials
Chart MEDICENNA THERAPEUTICS CORP.
Duration :
Auto.
2 months
3 months
6 months
9 months
1 year
2 years
5 years
10 years
Max.
Period :
Day
Week
Full-screen chart
Technical analysis trends MEDICENNA THERAPEUTICS CORP.
Short Term
Mid-Term
Long Term
Trends
Neutral
Bearish
Bearish
Technical analysis
Income Statement Evolution
Please enable JavaScript in your browser's settings to use dynamic charts.
More Financials
Consensus
Sell
Buy
Mean consensus
BUY
Number of Analysts
6
Last Close Price
1,36 CAD
Average target price
11,48 CAD
Spread / Average Target
744%
Consensus
EPS Revisions
Please enable JavaScript in your browser's settings to use dynamic charts.
More Estimates Revisions
Managers and Directors
Fahar Merchant
Chairman, President & Chief Executive Officer
Elizabeth Williams
Chief Financial Officer & Secretary
Martin Bexon
Chief Medical Officer
Albert George Beraldo
Independent Non-Executive Director
Chandrakant J. Panchal
Lead Independent Non-Executive Director
More about the company
Sector and Competitors
1st jan.
Capi. (M$)
MEDICENNA THERAPEUTICS CORP.
-35.24%
61
MODERNA, INC.
-45.70%
54 855
LONZA GROUP AG
-27.63%
40 862
IQVIA HOLDINGS INC.
-26.03%
39 504
SEAGEN INC.
-12.27%
24 966
ICON PUBLIC LIMITED COMPANY
-31.87%
17 153
More Results
Slave